Paloma Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Paloma Partners’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-24,992	Closed	-$50K	–	2298
2020 Q2	$50K	Buy	+24,992	New	+$49K	﹤0.01%	1992
2019 Q4	–	Sell	-42,800	Closed	-$129K	–	2359
2019 Q3	$129K	Buy	+42,800	New	+$133K	﹤0.01%	1815
2019 Q2	–	Sell	-15,903	Closed	-$88K	–	2003
2019 Q1	$88K	Buy	15,903 +4,903	+45%	+$29.8K	﹤0.01%	1606
2018 Q4	$73K	Buy	+11,000	New	+$89.1K	﹤0.01%	1137
2017 Q4	–	Sell	-69,521	Closed	-$854K	–	2137
2017 Q3	$854K	Buy	69,521 +9,307	+15%	+$137K	0.01%	1236
2017 Q2	$991K	Sell	60,214 -10,458	-15%	-$162K	0.01%	1202
2017 Q1	$1.01M	Buy	70,672 +12,967	+22%	+$192K	0.01%	1236
2016 Q4	$798K	Buy	+57,705	New	+$926K	0.01%	1284
2014 Q3	–	Sell	-2,611	Closed	-$29K	–	1185
2014 Q2	$29K	Buy	+2,611	New	+$28K	﹤0.01%	1069

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Paloma Partners's LXRX Position: Q3 2020 in Review

Paloma Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2020, closing a stake of 24,992 shares — an estimated $50K sold.

Paloma Partners first reported a position in LXRX in Q2 2014 and held it in 9 quarters. The position peaked at $1.01M in Q1 2017. 91 funds tracked by Wall St. Rank hold LXRX as of Q3 2020.

Paloma Partners reported no remaining Lexicon Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 24,992 Lexicon Pharmaceuticals shares in Q3 2020, an estimated $50K.
Paloma Partners first reported a position in Lexicon Pharmaceuticals in Q2 2014 and held it in 9 quarters.
Paloma Partners's Lexicon Pharmaceuticals position peaked at $1.01M in Q1 2017.
91 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.